Enliven Therapeutics Inc (ELVN) Shares See 67.31% Rise Over Last Week

Ulysses Smith

At the time of writing, Enliven Therapeutics Inc [ELVN] stock is trading at $26.0, up 11.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The ELVN shares have gain 67.31% over the last week, with a monthly amount glided 33.40%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on June 16, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $37. Previously, BTIG Research started tracking the stock with Buy rating on December 13, 2024, and set its price target to $42. On September 09, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $37 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $32 on June 11, 2024. Mizuho initiated its recommendation with a Buy and recommended $34 as its price target on April 09, 2024. Jefferies started tracking with a Buy rating for this stock on March 29, 2023, and assigned it a price target of $27.

For the past year, the stock price of Enliven Therapeutics Inc fluctuated between $13.30 and $25.59. Currently, Wall Street analysts expect the stock to reach $43.33 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $26.0 at the most recent close of the market. An investor can expect a potential return of 66.65% based on the average ELVN price forecast.

Analyzing the ELVN fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.25 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

It is important to note that Enliven Therapeutics Inc [NASDAQ:ELVN] has a current ratio of 32.95. On the other hand, the Quick Ratio is 32.95, and the Cash Ratio is 6.94.

Transactions by insiders

Recent insider trading involved Lyssikatos Joseph P, Officer, that happened on Jan 09 ’26 when 75000.0 shares were purchased. Officer, Kintz Samuel completed a deal on Jan 09 ’26 to buy 75000.0 shares. Meanwhile, Officer Patel Anish bought 48300.0 shares on Jan 09 ’26.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.